drugset / Trial / NCT07504796
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.
Timeline
- Start
- 2026-04-13
- Primary completion
- 2029-05
- Completion
- 2031-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Nivolumab | Monoclonal antibody | 480 mg | — |
| Background | Relatlimab | Monoclonal antibody | 160 mg | — |